GLP-1 receptor agonist drugs — including Novo Nordisk's Ozempic, Wegovy, and Rybelsus, and Eli Lilly's Mounjaro and Zepbound — have generated over $40 billion in annual sales while allegedly causing severe gastrointestinal injuries that manufacturers failed to adequately disclose. Over 3,100 lawsuits are consolidated in MDL 3094 in the Eastern District of Pennsylvania, with a separate NAION vision-loss MDL (3163) established in December 2025.
From the docket
Google Trends data recorded large week-over-week increases in searches for terms including "ozempic lawsuit 2025," "ozempic recall 2025," "ozempic news," and "tirzepatide side effects," with some terms rising several hundred percent and one search ("what is ozempic 2.0") marked as a breakout term.
Google Trends data recorded sharp week-over-week increases in searches for terms including "ozempic news" (up 2100%), "ozempic lawsuit 2025" (up 550%), "ozempic recall 2025" (up 500%), and "tirzepatide side effects" (up 500%), signaling heightened public interest in Ozempic-related legal and safety topics.
The FDA posted a Class I recall for specific Omnipod 5 pod models manufactured by Insulet Corporation. According to the recall notice, a manufacturing defect can damage the external soft cannula, causing insulin to leak around the pod rather than being delivered to the user. The FDA noted that failure to deliver insulin properly could lead to serious health consequences.
Google Trends data detected on June 24, 2026 shows that searches for terms including 'ozempic lawsuit,' 'ozempic recall 2025,' and 'ozempic news' surged dramatically week-over-week, with some terms reaching breakout status. Search interest in semaglutide side effects also rose notably during the same period.
Google Trends data detected major week-over-week increases in searches related to Ozempic lawsuits, recalls, and side effects around June 24, 2026. Search terms including 'ozempic news' rose 2,050%, 'ozempic lawsuit 2025' rose 1,950%, and 'ozempic recall 2023' rose 1,100%. Terms like 'ozempic lawsuit' and 'ozempic news today' also showed breakout or significant growth.
JPML establishes MDL 3163 for NAION vision-loss claims against Novo Nordisk. Approximately 29 cases consolidated with rapid growth expected. Expert discovery ongoing in the GI MDL; bellwether trials expected mid-2026.
MDL judge rules that gastroparesis plaintiffs must have a properly performed gastric emptying study confirming delayed emptying at time of diagnosis. May narrow plaintiff pool but strengthens remaining cases.
FDA updates Ozempic label to state drug is "not recommended in patients with severe gastroparesis" and adds intestinal obstruction warning — the first explicit gastroparesis language on the label.
JAMA Ophthalmology study finds semaglutide users face dramatically elevated NAION risk (8.9% vs 1.8% in diabetic patients). EMA requires European label update in August 2024; Novo Nordisk does not update U.S. labels.
The JPML consolidates GLP-1 GI injury cases into MDL 3094 in the Eastern District of Pennsylvania before Judge Karen S. Marston. Thousands of cases are transferred.
Sodhi et al. publish landmark JAMA study finding GLP-1 agonists associated with 3.67x gastroparesis risk, 4.22x bowel obstruction risk, and 9.09x pancreatitis risk among weight-loss patients. Triggers wave of lawsuits.
FDA updates Ozempic labeling to add ileus as a post-marketing adverse reaction. This is the first official acknowledgment of severe GI motility effects beyond nausea and vomiting.
Eli Lilly's Mounjaro (tirzepatide) approved for type 2 diabetes. Later approved as Zepbound for weight loss in November 2023. The dual GIP/GLP-1 agonist produces even greater weight loss than semaglutide.
FDA approves higher-dose semaglutide (Wegovy 2.4mg) for chronic weight management. Sales explode as social media drives demand for the "skinny shot." Off-label Ozempic prescriptions for weight loss also surge.
FDA approves semaglutide injection (Ozempic) for type 2 diabetes. Label includes thyroid cancer Black Box Warning and GI side effects but does not name gastroparesis.
Case results
$9B
$9,000,000,000
Takeda's Actos bladder cancer MDL produced a $9 billion jury verdict (later reduced) — a comparable pharmaceutical failure-to-warn case involving a diabetes drug with cancer risks the manufacturer concealed.
$4.85B
$4,850,000,000
Merck's Vioxx global settlement of $4.85 billion for cardiovascular injuries from a drug with suppressed safety data — the gold standard comparable for pharmaceutical failure-to-warn mass tort settlements.
$775M
$775,000,000
Bayer/J&J settled Xarelto GI bleeding claims for $775 million — a comparable pharmaceutical MDL involving GI side effects of a blockbuster drug.
$300,000 avg
PPI kidney injury settlements averaged $300,000 per claim — a comparable pharmaceutical GI drug mass tort. GLP-1 gastroparesis claims are expected to settle in a similar or higher range.
Stay informed
No phone call required. We will email you when there is meaningful news — new filings, settlements, or important deadlines.
Full case details
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View the full Ozempic / GLP-1 case page →